Biosimilarity between Humira® and the Biosimilar Candidate SB5 in Product Quality

被引：0
|
作者：
Lee, Nayoung [1 ]
Kim, Minlee [1 ]
Lee, JongAh Joanne [1 ]
Kim, Soohwan [1 ]
Yang, Hahymn [1 ]
机构：
[1] Samsung Bioepis, Incheon, South Korea
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2495
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis
    Bruni, Cosimo
    Gentileschi, Stefano
    Pacini, Giovanni
    Bardelli, Marco
    Tofani, Lorenzo
    Bartoli, Francesca
    Baldi, Caterina
    Cometi, Laura
    Fiori, Ginevra
    Nacci, Francesca
    Cantarini, Luca
    Guiducci, Serena
    Moggi-Pignone, Alberto
    Frediani, Bruno
    Matucci-Cerinic, Marco
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021, 13
  • [32] Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature
    Park, Dongkuk
    Yun, Jihoon
    Hwang, Su-Jeong
    Park, Su Jin
    ADVANCES IN THERAPY, 2019, 36 (02) : 442 - 450
  • [33] Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis
    Weinblatt, Michael E.
    Baranauskaite, Asta
    Niebrzydowski, Jaroslaw
    Dokoupilova, Eva
    Zielinska, Agnieszka
    Jaworski, Janusz
    Racewicz, Artur
    Pileckyte, Margarita
    Jedrychowicz-Rosiak, Krystyna
    Cheong, Soo Yeon
    Ghil, Jeehoon
    ARTHRITIS & RHEUMATOLOGY, 2018, 70 (01) : 40 - 48
  • [34] A RANDOMISED PHASE I PHARMACOKINETIC STUDY COMPARING HIGH-CONCENTRATION, LOW-VOLUME, AND CITRATE-FREE SB5 (40 MG/0.4 ML) WITH PRIOR SB5 FORMULATION, AND ADALIMUMAB BIOSIMILAR, IN HEALTHY MALE SUBJECTS
    Ahn, S. S.
    Lee, M.
    Baek, Y.
    Lee, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 590 - 590
  • [35] SUSTAINED EFFICACY AND COMPARABLE SAFETY AND IMMUNOGENICITY AFTER TRANSITION TO SB5 (AN ADALIMUMAB BIOSIMILAR) VS CONTINUATION OF THE ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULT OF PHASE III STUDY
    Weinblatt, M.
    Baranauskaite, A.
    Niebrzydowski, J.
    Dokoupilova, E.
    Zielinska, A.
    Sitek-Ziolkowska, K.
    Jaworski, J.
    Racewicz, A.
    Pileckyte, M.
    Jedrychowicz-Rosiak, K.
    Zhdan, V.
    Cheong, S. Y.
    Ghil, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 487 - 487
  • [36] USABILITY AND SAFETY OF SB5 (AN ADALIMUMAB BIOSIMILAR) PRE-FILLED SYRINGE AND PRE-FILLED PEN IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Ghil, J.
    Niebrzydowski, J.
    Zielinska, A.
    Lee, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 556 - 557
  • [37] Maintenance of clinical remission with SB5 biosimilar after switch from adalimumab originator: Real-life experience of a tertiary referral centre
    Dragoni, G.
    Pieraccini, A.
    Bagnoli, S.
    Caini, S.
    Macri, G.
    Rogai, F.
    Milani, S.
    Galli, A.
    Milla, M.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S515 - S515
  • [38] LONG-TERM OUTCOMES FOLLOWING A SWITCH FROM ORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5 (IMRALDI) IN A REAL-WORLD IBD COHORT
    Derikx, Lauranne
    Plevris, Nikolas
    Lucaciu, Laura
    Dolby, Heather
    Rees, Caitlin
    Lyons, Mathew
    Siakavellas, Spyros I.
    Noble, Colin L.
    O'Hare, Claire
    Merchant, Lynne M.
    Arnott, Ian
    Jones, Gareth R.
    Lees, Charlie W.
    GASTROENTEROLOGY, 2021, 160 (06) : S704 - S704
  • [39] MAINTENANCE OF CLINICAL REMISSION WITH SB5 BIOSIMILAR AFTER SWITCH FROM ADALIMUMAB ORIGINATOR: REAL-LIFE EXPERIENCE OF A TERTIARY REFERRAL CENTER
    Dragoni, G.
    Pieraccini, A.
    Bagnoli, S.
    Caini, S.
    Macri, G.
    Rogai, F.
    Milani, S.
    Galli, A.
    Milla, M.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : S120 - S120
  • [40] Analytical Characterization for Similarity Assessment Between an Aflibercept Biosimilar SB15 and Reference Product (Eylea®)
    Lee, Hangyeore
    Huh, Jongcheol
    Kim, Dayoung
    Lee, Soye
    Lee, Jaeil
    Lee, Jungmin
    Kim, Beom Chan
    Song, Jinsu
    OPHTHALMOLOGY AND THERAPY, 2024, 13 (08) : 2209 - 2225
12345